- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
53
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
53 companies
KalVista Pharmaceuticals
Market Cap: US$674.3m
A biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
KALV
US$13.09
7D
20.2%
1Y
33.6%
Arcturus Therapeutics Holdings
Market Cap: US$231.0m
Engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
ARCT
US$7.77
7D
-6.3%
1Y
-57.6%
Oncolytics Biotech
Market Cap: US$109.3m
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments.
ONCY
US$1.03
7D
1.0%
1Y
5.1%
Dyadic International
Market Cap: US$32.7m
A biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.
DYAI
US$0.91
7D
-2.4%
1Y
-19.2%
Aprea Therapeutics
Market Cap: US$6.9m
A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
APRE
US$1.21
7D
-1.6%
1Y
-62.8%
Geron
Market Cap: US$734.1m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.11
7D
3.3%
1Y
-69.8%
Annexon
Market Cap: US$387.9m
A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
ANNX
US$2.71
7D
-5.9%
1Y
-55.7%
GeoVax Labs
Market Cap: US$13.9m
A clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
GOVX
US$0.45
7D
-12.1%
1Y
-81.4%
Celcuity
Market Cap: US$4.0b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$92.68
7D
24.4%
1Y
632.1%
Dynavax Technologies
Market Cap: US$1.3b
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally.
DVAX
US$11.06
7D
2.1%
1Y
-9.4%
Heron Therapeutics
Market Cap: US$203.5m
A commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
HRTX
US$1.10
7D
0%
1Y
-7.6%
Immunocore Holdings
Market Cap: US$1.8b
A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
IMCR
US$35.97
7D
7.4%
1Y
13.9%
Mirum Pharmaceuticals
Market Cap: US$3.6b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$69.25
7D
2.3%
1Y
49.7%
Amicus Therapeutics
Market Cap: US$2.9b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$9.38
7D
5.4%
1Y
-7.0%
Akebia Therapeutics
Market Cap: US$467.0m
A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
AKBA
US$1.67
7D
-18.1%
1Y
-6.7%
Organogenesis Holdings
Market Cap: US$788.1m
A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
ORGO
US$6.10
7D
8.3%
1Y
58.0%
Natera
Market Cap: US$27.7b
A diagnostics company, provides molecular testing services worldwide.
NTRA
US$204.18
7D
2.3%
1Y
39.8%